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Background: Hydrocephalus is a recognised complication of human immunodeficiency virus (HIV)-related opportunistic
infections. Symptomatic raised cerebrospinal fluid pressure can be treated with ventriculoperitoneal shunt insertion (VPS).
In HIV-infected patients however, there is a concern that VPS might be associated with unacceptably high
rates of mortality. We aim to systematically review and appraise published literature to determine reported
outcomes and identify predictors of outcome following VPS in relevant subgroups of HIV-infected adults.
Methods: The following electronic databases will be searched: The Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE (PubMed), EMBASE, CINAHL (EBSCOhost), LILACS (BIREME), Research Registry (www.
researchregistry.com), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov
(www.clinicaltrials.gov) and OpenSIGLE database. Any randomised studies, cohort studies, case-control studies,
interrupted time series or sequential case series reporting survival following VPS in HIV-infected individuals will
be included. If high-quality homogenous studies exist, meta-analysis will be conducted to determine 1-, 6- and 12-month
mortality with comparison made between underlying aetiologies of hydrocephalus.
Discussion and conclusion: This study will generate a comprehensive review of VPS in HIV-infected patients for
publication. The primary outcome of meta-analysis is 12-month survival. If only low-quality, heterogeneous
studies are available, this study will demonstrate this deficiency and will be of value in justifying and aiding
the design of future studies.
Systematic review registration: PROSPERO CRD42016052239Background
Description of the condition
Human immunodeficiency virus (HIV) is a lentivirus
and is the causative organism for the acquired immuno-
deficiency syndrome (AIDS) [1]. Two major subtypes of
HIV—HIV-1 and HIV-2—are known to exist [2]. Over
95% of patients infected with HIV will, without treat-
ment, develop progressive immunodeficiency as indi-
cated by falling CD4-positive T cell counts and/or
development of AIDS defining illnesses within 10 years* Correspondence: james.loan@nhs.net
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is slower in those infected with HIV-2 compared with
the globally more common HIV-1 [1, 2].
HIV infection is associated with myriad central
nervous system (CNS) sequelae. These include, but are
not limited to, toxoplasmosis, primary CNS lymphoma
(PCNSL), tuberculous meningitis (TBM), cryptococcal
meningitis and immune reconstitution inflammatory
syndrome (IRIS) [5–8]. These may all disrupt cerebro-
spinal fluid (CSF) circulation causing an abnormal accu-
mulation of CSF within the cranium, an associated rise
in intracranial pressure and consequent cerebral injury.
This condition is called hydrocephalus. In communica-
ting hydrocephalus, ventricular CSF is continuous with
CSF in the subarachnoid space. Communicatingle is distributed under the terms of the Creative Commons Attribution 4.0
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duction or reduced CSF resorption [9]. In non-
communicating hydrocephalus, CSF passage from the
ventricles to subarachnoid space is occluded. With time
and successful treatment of the primary pathology, acute
hydrocephalus might resolve, with normalisation of CSF
pressure, or become associated with chronically raised
CSF pressure [10]. Age-related cerebral tissue loss as
well as HIV-associated neurocognitive disorder are
associated with enlargement of CSF spaces due to
generalised brain atrophy and may result in the radio-
logical appearance of hydrocephalus but are associated
with normal CSF pressure and flow, so-called hydro-
cephalus ex vacuo [9, 11]. This is not an indication for
surgical treatment [9].
Meningeal infections including TBM, cryptococcal
meningitis and bacterial meningitis can impair CSF
resorption at arachnoid granulations, resulting in
communicating hydrocephalus [10, 12]. TBM, which is
associated with thick basal exudate, can also result in
non-communicating hydrocephalus [13]. TBM in the
context of HIV infection appears to be associated with
substantially increased morbidity and mortality
compared with HIV non-infected patients [14, 15]. This
might arise because of synergistic effects of HIV and
tuberculosis in the CNS causing depressed monocyte
and microglial mediated immunity and dysregulated
cytokine production [16–21]. Hydrocephalus in TBM
frequently persists following successful antimicrobial
treatment [22]. Conversely, the majority of HIV-
infected patients with raised CSF pressures secondary
to cryptococcal meningitis (typically communicating
hydrocephalus) experience normalising of CSF pres-
sure and resolution of hydrocephalus following suc-
cessful antimicrobial therapy [10]. A small proportion
does require temporary CSF diversion for initial acute
hydrocephalus [23]. Mass lesions such as toxoplasmo-
sis, PCNSL, metastases from HIV-associated non-CNS
malignancy and tuberculoma can trigger the develop-
ment of non-communicating hydrocephalus by occlu-
sion of ventricular outflow pathways [24, 25]. In these
instances, hydrocephalus resolution post-treatment is
dependent on restoration of normal ventricular
outflow pathway anatomy. IRIS affecting the CNS is
defined by a transient worsening or development of
new inflammatory lesions during immune reconstitu-
tion around infective foci and might also present with
hydrocephalus secondary to meningitis or mass
lesions [26, 27].
Epidemiology
As of 2015, it was estimated that 36.7 million people
globally were living with HIV infection [28]. Of these,
19.0 million live in Eastern and Southern Africa [28].HIV infection disproportionately affects certain vulner-
able populations including intravenous substance
misusers, sex workers and their clients, men who have
sex with men and transgender people [28]. The risk of
Mycobacterium tuberculosis disease is estimated to be 20
times greater in HIV-infected patients compared with
their HIV non-infected counterparts, an effect which is
most pronounced in low-income populations [29, 30].
As such, one cadaveric study conducted in the Ivory
Coast in 1991 found that 32% of in-hospital deaths of
HIV-infected patients were a result of tuberculosis with
TBM affecting 20% of these [31]. The increasing availabil-
ity of antiretroviral therapy (ART) has seen a decline in
the incidence of new opportunistic intracranial infections,
PCNSL and reduced AIDS-related deaths [5, 32, 33].
However, with improved survival and ongoing HIV trans-
mission, the global prevalence of HIV and the associated
burden of chronic disease continues to rise [28].
The incidence of hydrocephalus associated with
HIV infection is poorly quantified at present. Small
studies comparing clinical and radiological character-
istics of HIV-associated and HIV non-associated
patients with conditions associated with hydroceph-
alus provide some information: HIV-associated TBM
appears to be associated with lower rates of non-
communicating hydrocephalus than HIV non-
associated TBM [34], and in some studies, over 50%
of patients with cryptococcal meningitis, which occurs
almost exclusively in HIV-infected patients, have
exhibited raised CSF pressures [10]. However, non-
communicating hydrocephalus is uncommon in
cryptococcal meningitis [10, 35]. It is also important
to note that any other cause of hydrocephalus may
also be seen in the HIV-infected population; hence,
adults might suffer the ongoing effects of infant-onset
or congenital hydrocephalus. This is estimated to
affect 1.1 in 1000 infants and 32 per 10,000 births
and may be due to anatomical abnormalities such as
neural tube defects and Chiari malformations or arise
secondary to perinatal insults such as intraventricular
haemorrhage and bacterial meningitis [36]. In HIV
non-infected high-income populations, intracranial
haemorrhage and malignancy account for 45 and 30%
of new cases of adult onset hydrocephalus, respect-
ively [37]. A lack of dedicated epidemiological
research concerning HIV-associated hydrocephalus
makes data from these small studies difficult to
generalise, and little is known about the distribution
of non-infective causes of hydrocephalus associated
with HIV.
Description of the intervention
A ventriculoperitoneal shunt (VPS) is a surgically
implanted device that allows flow of fluid from the
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of a silicone ventricular catheter that is inserted through
a single burr hole, using either image guidance or ana-
tomical landmarks to locate the ventricle. The catheter
is sometimes rifampicin and clindamycin or silver im-
pregnated [38]. It is connected to a valve that is usually
placed in the subgaleal space. The valve can be pressure
or flow regulated and may contain an antisiphon device
[39]. This is connected to a length of distal tubing that is
tunnelled subcutaneously from the valve site to the level
of the abdomen where it is inserted through the abdom-
inal wall into the peritoneal cavity where the distal
catheter tip sits.
A functioning VPS provides a permanent pathway for
ventricular CSF outflow and allows for normalisation of
CSF pressure in hydrocephalus. Common complications
following successful VPS include shunt infection, ventri-
culitis, proximal catheter occlusion or migration, shunt
fracture, over drainage and distal catheter occlusion [40].
In one US cohort, 21% of adults who underwent VPS
between 1990 and 2000 suffered a complication within
the first year and 26% required replacement or removal
of the shunt during the study period [41]. One cohort of
mostly paediatric patients who underwent VPS between
2004 and 2007 in Kenya, a low-middle-income country
with high HIV prevalence, there was a 2-year cumulative
malfunction rate of 35% with 59.8% having “poor
outcome” and 8.5% mortality [42–44]. However, follow-
up was reported as incomplete and this might not there-
fore been an underestimate of the complication rate in
such a setting.
Alternatives to VPS include ventriculoatrial shunting
where the distal catheter tip is sited in the right cardiac
atrium and ventriculopleural shunting where it is sited
in the pleural cavity. In some instances, an external
ventricular drain (EVD) may be sited in preference to a
shunt [39]. For this, a ventricular catheter is placed and
the distal tip externalised through the scalp and
connected without a valve to a drain mounted at a spe-
cific height above the tragus of the ear. This allows grav-
ity to limit CSF flow via the catheter below a desired
pressure. However, this is only a temporary means of
CSF diversion. For some cases of communicating hydro-
cephalus, it may be sufficient to drain CSF through serial
lumbar puncture or a lumbar drain [39]. Lumbar drains
may be externalised using a similar system to an EVD or
tunnelled and have the distal tubing placed in the peri-
toneal cavity—a lumboperitoneal shunt [39]. In cases of
non-communicating hydrocephalus, it is sometimes pos-
sible to surgically divide the lamina terminalis or endo-
scopically conduct a third ventriculostomy (ETV) to
allow for flow of ventricular CSF to the subarachnoid
space [13]. However, this procedure is challenging—par-
ticularly in TBM [13]—and requires significant expertiseand equipment that may not be available in emergency
or resource-limited settings.
Why it is important to do this review
A proportion of patients infected with HIV develop
hydrocephalus as a complication of CNS opportunistic
infections. As described above, infectious aetiologies of
hydrocephalus are over-represented in HIV-infected
patients and HIV directly impacts on the pathological
processes in intracranial infection. The literature from
HIV non-infected patient populations therefore cannot
be generalised to those with HIV infection.
VPS can be immediately life-saving in acute hydro-
cephalus and may be the sole treatment option for
patients who are dependent on CSF diversion following
emergency EVD insertion and are not candidates for
ETV. However, two of the most cited studies comparing
VPS in HIV-infected patients with TBM to HIV non-
infected counterparts demonstrated mortality rates in
excess of 60% in HIV-infected patients [45, 46]. Small
numbers of HIV-infected patients in these studies
achieved good outcome following VPS [45, 46]. Better
outcomes have been reported following VPS insertion
for other causes of HIV-associated hydrocephalus [47,
48]. To determine if the existing literature is sufficient to
inform selection of HIV-infected patients for VPS in
clinical practice, it is necessary for a systematic review to
be conducted.
Objectives
Our objectives were to compare post-VPS mortality,
VPS infection, VPS malfunction and clinical outcome
and rates of other complications at 1, 6 and 12 months
between different aetiologies of HIV-associated hydro-
cephalus using quantitative meta-analysis and produc-
tion of a narrative review. They would allow the
identification of baseline patient characteristics which
are predictive of good outcome following VPS in HIV
infection.
Methods
This protocol was produced with reference to the
PRISMA-P checklist (see Additional file 1).
Inclusion criteria
Types of studies
We will include the following study designs: randomised
clinical trials (RCTs), one- and two-group cohort studies,
case-control studies, interrupted time series and con-
secutive case series. Descriptive, non-comparative stud-
ies of relevant populations will be eligible for inclusion.
Studies reporting data on a population with a subset of
HIV-infected individuals will only be included if
Loan et al. Systematic Reviews  (2017) 6:201 Page 4 of 10outcome data on the subpopulation of HIV-infected
patients is reported.
Types of participants
All studies of patients aged 16 years or older who have
undergone a VPS procedure and have a positive sero-
logical diagnosis of HIV infection or a detectible HIV
viral load will be included, regardless of the presence of
any other complicating CNS pathology.
Types of interventions
Studies of patients who have undergone a VPS proced-
ure using any type of catheter, valve or insertion
technique will be included.
Types of outcome measures
We will include studies of primary data that report mea-
sures of overall survival, AIDS-specific mortality or VPS
failure. We define VPS failure in all patient groups as
any complication requiring shunt removal or revision.
Studies reporting perioperative complications of VPS
will additionally be included for secondary analysis.
Outcomes
Our study’s primary outcome will be 1-year post-VPS
survival with comparison between all identified aetiol-
ogies of hydrocephalus in HIV-infected patients treated
with VPS. We define separate aetiologies as being differ-
ent sites of anatomical abnormality, with congenital and
acquired causes considered separate: subarachnoid
haemorrhage, intraventricular haemorrhage and different
suspected or proven pathogens for infectious causes.
Secondary outcomes will be survival at 1 and 6 months
andAIDS-specific mortality, VPS failure, rates of
perioperative complications and measures of outcome
using validated outcome measures [49–51] at 1 month,
6 months and 1 year post-VPS insertion. For all
measures, comparison will be made between aetiologies
of hydrocephalus.
Search methods for the identification of studies
Scoping searches
Scoping searches have been undertaken to identify
candidate studies and inform keyword selection for
electronic searching [15, 45–47].
Electronic searches
We will search the following electronic databases: The
Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE (PubMed), EMBASE, CINAHL
Plus (EBSCOhost), LILACS (BIREME), Research Registry
(www.researchregistry.com), the metaRegister of Controlled
Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.
gov (www.clinicaltrials.gov) and African Journals Online(AJOL). Grey literature searching will be performed using
the OpenGREY database. There will be no date restrictions
in electronic searches. Our search sensitivity has been
ensured by confirming that candidate studies identified dur-
ing scoping searches are included in the search yields. See
Appendix 1 for full search strategies.
Searching other resources
We will examine the reference lists of included studies
to identify any additional studies for inclusion. Experts
in relevant fields will be consulted and asked to identify
key studies. Any studies identified for consideration of
inclusion by these consults that were not detected by
our search will be documented in our final report. We
will not hand search any conference proceedings or
journals. Disagreement will be resolved through consensus
discussion and/or consideration of a third author (GF).
Data extraction and management
Data will be extracted using standardised proformas
(Appendix 2) and entered into review manager [52] by
two authors (JL, NM).We will use the software package
EndNote for reference management [53].
Data collection and analysis
Selection of studies
Two review authors (JL, NM) will independently screen
all titles and abstracts yielded by the literature search.
During screening, studies will be scrutinised against
inclusion criteria. Those not meeting criteria will be
excluded. For those which meet the criteria or for
which it is impossible to tell if criteria are met on the
basis of title and abstract the full manuscript will be
sought and reviewed. Any subsequent exclusions will
be documented.
Assessment of risk of bias in included studies
Each included study will be independently assessed for
risk of bias by two study authors (JL, NM). Randomised
studies will be assessed using the ‘Risk of bias’ tool from
Chapter 8.5 of the Cochrane Handbook of Systematic
Reviews of Intervention [54]. Non-randomised studies
(NRS) will be assessed using the Canadian National
Collaborating Centre for Methods and Tools “Quality
Assessment Tool for Quantitative Studies” [55, 56]. Sum-
mary outcomes of these assessments will be presented.
Measures of effect
In the narrative review, we will summarise outcomes as
reported by each included study separately. If data com-
paring outcome across different aetiologies of hydro-
cephalus exists, we will report it. If meta-analysis is
performed, pooled odds ratios (OR) will be reported.
The primary outcome of any RCTs comparing VPS with
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multiple trials of the same interventions report similar
outcomes, meta-analysis will be conducted according to
guidance by the Cochrane Handbook of Systematic
Reviews of Interventions [54].Dealing with missing data
We will attempt to contact the authors of included
studies electronically for any unreported details. If,
following this, uncertainty remains, we will report
available data and state missing data. Studies with
missing mortality data will not be eligible for inclu-
sion in meta-analysis.Assessment of heterogeneity
On the basis of extracted data, studies will be compared
for clinical and methodological heterogeneity. Where ap-
parently homogenous studies report similar outcome
measures at similar time points, the I2 (%) and T2 statis-
tics will be calculated, with I2 greater than 50% suggest-
ing substantial heterogeneity. For estimation of statistical
heterogeneity, we will use odds of mortality between
aetiologies of HIV-associated hydrocephalus as the
measure of effect.Data synthesis
If substantial clinical, methodological or statistical
heterogeneity is detected or if no comparative studies are
included, we will not attempt meta-analysis and will
present solely a narrative review. If homogenous compara-
tive studies are identified, then meta-analysis of pooled
mortality data will be conducted using the Peto method.
OR at 12, 6 and 1 month post-VPS between pooled popu-
lations with different aetiologies of hydrocephalus will be
compared. If greater than 10 homogenous studies are in-
cluded for meta-analysis, meta-regression will be
attempted. Covariables for this will include, where reported,
age categories (16–24; 25–44; 45–59; ≥ 60), CD4+ cell
count, time from presentation to VPS, initial Glasgow
Coma Score [50], and shunt catheter type—either
conventional, antibiotic or silver impregnated. Where
not all variables are reported, regression will be con-
ducted using the maximum covariables reported by
all eligible studies. Where meta-analysis is performed,
sensitivity analysis will be undertaken to determine
the relative effects of inclusion of each individual
study, as well as RCTs and non-randomised studies
from different World Bank income categories: low-
income, lower-middle-income, upper-middle-income
and high-income economies. GRADEpro will be used
to summarise strength of available data [57].Protocol amendments
This is the original study protocol. Any subsequent
protocol amendments will be published on the
PROSPERO database of systematic reviews. Amend-
ments to the protocol manuscript following peer
review are documented (see Additional file 2).Discussion
HIV infection and HIV-associated hydrocephalus dispro-
portionately impact on patients from low-middle-
income countries [28]. Unfortunately, it is believed that
the neurosurgical management of CNS complications of
HIV infection has received relatively little research
attention, and consequently, guidelines for management
to date have been based on low-quality evidence [58, 59].
As outcome following VPS in HIV appears to be some-
what dependent on population income, it is important
that studies of outcome take into account population
demographics and that the study of low-middle-income
populations is urgently prioritised [41, 42]. This study will
begin to address this need by summarising existing
evidence to inform clinical practice in relevant popu-
lations where the data supports this. We also will
define deficiencies in existing literature and to guide
research direction towards meaningfully answering
relevant questions.Appendix 1
Search terms
MEDLINE (PubMed)
Abbreviated search strategy (full syntax available)
1. human
2. immunodeficiency
3. virus
4. 1 AND 2 AND 3
5. human immunodeficiency virus
6. HIV
7. acquired
8. immunodeficiency
9. 7 AND 8
10.acquired immunodeficiency syndrome
11.AIDS
12.4 OR 5 OR 6 OR 9 OR 10 OR 11
13.ventriculoperitoneal
14.ventric*
15.ventricular
16.14 OR 15
17.peritone*
18.peritoneal
19.17 OR 18
20.16 AND 19
21.VP
Loan et al. Systematic Reviews  (2017) 6:201 Page 6 of 1022.cerebrospinal
23.cerebrosp*
24.CSF
25.22 OR 23 OR 24
26.13 OR 20 OR 21 OR 25
27.shunt*
28.shunt
29.catheter*
30.catheter
31.diversion
32.divers*
33.27 OR 28 OR 29 OR 30 OR 31 OR 32
34.26 AND 33
35.ventriculoperitoneal shunt
36.34 OR 35
37.12 AND 36CENTRAL
1. Human
2. Immunodeficiency
3. Virus
4. 1 and 2 and 3
5. MeSH descriptor: [HIV] explode all trees
6. Human immunodeficiency virus
7. HIV
8. acquired
9. Immunodeficiency
10.8 and 9
11.acquired immunodeficiency syndrome
12.AIDS
13.MeSH descriptor: [Acquired Immunodeficiency
Syndrome] explode all trees
14.#4 or #5 or #6 or #7 or #10 or #11 or #12 or #13
15.ventriculoperitoneal
16.ventricular
17.peritoneal
18.16 and 17
19.VP
20.cerebrospinal
21.CSF
22.MeSH descriptor: [Cerebrospinal Fluid] explode all
trees
23.15 or 18 or 19 or 20 or 21 or 22
24.shunt
25.MeSH descriptor: [Cerebrospinal Fluid Shunts]
explode all trees
26.catheter
27.MeSH descriptor: [Catheters] explode all trees
28.diversion
29.#24 or #25 or #26 or #27 or #28
30.23 and 29
31.ventriculoperitoneal shunt32.MeSH descriptor: [Ventriculoperitoneal Shunt]
explode all trees
33.30 or 31 or 32
34.14 and 33
EMBASE
Unlimited search terms linked to Subject Heading
1. human/
2. immunodeficiency.mp. or immune deficiency/
3. virus/
4. 1 and 2 and 3
5. human immunodeficiency virus.mp. or Human
immunodeficiency virus/
6. HIV.mp. or Human immunodeficiency virus/
7. acquired.mp.
8. immunodeficiency.mp. or immune deficiency/
9. 7 and 8
10.acquired immunodeficiency syndrome.mp. or
acquired immune deficiency syndrome/
11.AIDS.mp. or acquired immune deficiency syndrome/
12.4 or 5 or 6 or 9 or 10 or 11
13.cerebrospinal fluid shunting/ or shunting/ or shunt
infection/ or hydrocephalus/ or brain ventricle
peritoneum shunt/ or ventriculoperitoneal.mp. or
cerebrospinal fluid/
14.ventricular.mp
15.brain ventricle peritoneum shunt/ or hydrocephalus/
or ventriculoatrial shunt/ or ventric*.mp.
16.14 or 15
17.peritoneum/ or peritone*.mp.
18.peritoneal catheter/ or peritoneal drain/ or
peritoneal.mp. or peritoneal cavity/
19.17 or 18
20.16 and 19
21.vp.mp.
22.cerebrospinal fluid level/ or cerebrospinal.mp. or
cerebrospinal fluid drainage system/ or cerebrospinal
fluid analysis/ or cerebrospinal fluid/ or
cerebrospinal fluid shunting/ or cerebrospinal fluid
drainage/
23.cerebrospinal fluid/ or cerebrosp*.mp
24.CSF.mp. or cerebrospinal fluid/
25.22 or 23 or 24
26.13 or 20 or 21 or 25
27.brain ventricle peritoneum shunt/ or shunt.mp.
or shunt occlusion/ or ventriculoatrial shunt/ or
shunt thrombosis/ or shunt failure/ or shunt
infection/
28.shunt*.mp.
29.catheter.mp. or catheter fracture/ or intrathecal
catheter/ or drainage catheter/ or catheter
infection/ or neurological catheter/ or catheter
care/ or catheter leakage/ or subdural catheter/ or
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catheter sheath/ or catheter thrombosis/ or
ventriculostomy catheter/ or catheter/ or catheter
dislocation/ or antimicrobial catheter/ or catheter
migration/ or catheter complication/ or catheter
valve/ or intracranial catheter/
30.catheter/
31.diversion.mp.
32.divers*.mp.
33.27 or 28 or 29 or 30 or 31 or 32
34.26 and 33
35.ventriculoperitoneal shunt.mp. or brain ventricle
peritoneum shunt/
36.34 or 35
37.12 and 36
CINAHL Plus (EBSCOhost)
S1. MW Human immunodeficiency virus.
S2. TI Human AND TI Immunodeficiency AND TI
virus.
S3. (MH “HIV-Infected Patients”) OR (MH “HIV
Protease Inhibitors”) OR (MH “HIV Seropositivity”)
OR (MH “AIDS Serodiagnosis”).
S4. TX acquired OR TX immunodeficiency.
S5. MW aquired immunodeficiency syndrome OR TX
AIDS.
S6. S1 OR S2 OR S3 OR S4 OR S5.
S7. TX ventric* OR TX ventricular.
S8. TX peritoneal AND TX peritone*.
S9. S7 AND S8.
S10. TX ventriculoperitoneal.
S11. TX VP.
S12. TX cerebrospinal OR MW cerebrospinal OR TX
cerebrosp*.
S13. TX CSF.
S14. S12 OR S13.
S15. S9 OR S10 OR S11 OR S14.
S16. TX shunt* OR MW shunt.
S17. TX catheter* OR MW catheter.
S18. MW diversion OR TX divers*.
S19. S16 OR S17 OR S18.
S20. S15 AND S19.
S21. TX ventriculoperitoneal shunt OR MW
ventriculoperitoneal shunt.
S22. S20 OR S21.
S23. S6 AND S22
LILACS (VHL)
((((human) AND (immunodeficiency) AND (virus))
OR (human immunodeficiency virus) OR (HIV) OR
((acquired) AND (immunodeficiency)) OR (acquired
immunodeficiency syndrome) OR (AIDS))) AND
(((ventriculoperitoneal) OR (((ventric*) OR (ventricular))
AND ((peritone*) OR (peritoneal))) OR (VP) OR((cerebrospinal) OR (cerebrosp*) OR (CSF)))) AND
((shunt*) OR (shunt) OR (catheter*) OR (catheter) OR
(diversion) OR (divers*) OR (ventriculoperitoneal shunt))Research Registry (www.researchregistry.com)
Individual searches for:
1. HIV
2. AIDS
3. acquired immunodeficiency syndrome
4. Human immunodeficiency
5. ventriculoperitoneal
6. hydrocephalus
7. cerebrospinal
8. CSF
9. shuntThe metaRegister of Controlled Trials (mRCT)
(www.controlled-trials.com)
((((human) AND (immunodeficiency) AND (virus)) OR
(human immunodeficiency virus) OR (HIV) OR
((acquired) AND (immunodeficiency)) OR (acquired
immunodeficiency syndrome) OR (AIDS))) AND
(((ventriculoperitoneal) OR (((ventric*) OR (ventricular))
AND ((peritone*) OR (peritoneal))) OR (VP) OR
((cerebrospinal) OR (cerebrosp*) OR (CSF)))) AND
((shunt*) OR (shunt) OR (catheter*) OR (catheter) OR
(diversion) OR (divers*) OR (ventriculoperitoneal shunt))ClinicalTrials.gov (www.clinicaltrials.gov)
(HIV OR (Human immunodeficiency virus) OR AIDS)
AND ((Ventriculoperitoneal Shunt) OR (CSF diversion)
OR Hydrocephalus)OpenGREY
((((human) AND (immunodeficiency) AND (virus))
OR (human immunodeficiency virus) OR (HIV) OR
((acquired) AND (immunodeficiency)) OR (acquired
immunodeficiency syndrome) OR (AIDS))) AND
(((ventriculoperitoneal) OR (((ventric*) OR (ventricular))
AND ((peritone*) OR (peritoneal))) OR (VP) OR
((cerebrospinal) OR (cerebrosp*) OR (CSF)))) AND
((shunt*) OR (shunt) OR (catheter*) OR (catheter) OR
(diversion) OR (divers*) OR (ventriculoperitoneal shunt))African Journals Online (AJOL)
(((human immunodeficiency virus) OR (acquired
immunodeficiency syndrome) OR (AIDS))) AND
(((ventriculoperitoneal) OR (((ventric*) OR (VP) OR
((cerebrosp*) OR (CSF)))) AND ((shunt*) OR
(catheter*) OR (divers*) OR (ventriculoperitoneal
shunt))
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Data to be extracted Data
Population Age range
Diagnostic modality for
hydrocephalus/CSF hypertension
Diagnostic modality for underlying
aetiology
CD4+ cell count range (for each
underlying aetiology)
Country population derived from
Severity of disease at baseline
(using GCS, palur grade, MRC
scale, GOS or mRS) for each
underlying aetiology
Communicating or non-
communicating hydrocephalus
Intervention Primary VPS or following EVD
Catheter type (plain silicon,
antibiotic impregnated, silver
impregnated)
Comparison intervention Description of intervention
Frequency of intervention
Outcome (for each
underlying aetiology
and intervention)
Survival at 1, 6 and 12 months
Causes of death at 1, 6 and
12 months
Rate of shunt failure at 1, 6 and
12 months
Rates of complication at 1, 6
and 12 months
Validated outcome measure at
1, 6 and 12 monthsAdditional files
Additional file 1: PRISMA-P Checklist. Standardised reporting guideline
for production of systematic review protocol. (PDF 184 kb)
Additional file 2: Responses to peer reviewer comments. HIV VPS
Protocol Reviewers Responses. (DOCX 126 kb)
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reconstitution inflammatory syndrome; PCNSL: Primary central nervous
system lymphoma; RCT: Randomised clinical trial; TBM: Tuberculous
meningitis; VPS: Ventriculoperitoneal shunt
Acknowledgements
This protocol was produced as part of the third year of the MSc in Surgical
Sciences or Edinburgh Surgical Sciences Qualification www.essq.rcsed.ac.uk.
Funding
This study has received no external funding.Availability of data and materials
Not applicable.
Authors’ contributions
JJML designed the study and wrote the study protocol and is the protocol
guarantor (in detail, made the initial conception of the study and proposal
to Prof. Fieggen, conducted the background scoping searches, wrote every
draft of the protocol, determined the study inclusion criteria, study
outcomes, search strategy, risk of bias assessment, data extraction and
handling protocols and statistical methods). NM did the critical appraisal
of the study protocol (in detail, carried out the detection of typographic
errors). GM made the critical appraisal of the study protocol (in detail,
made the detection of typographic errors, advised on the non-inclusion
of progressive multifocal leukoencephalopathy in background, advised
on AIDS-specific mortality and advised on appropriate measures of
effect). GF is the study supervisor (in detail, suggested the initial reading for the
scoping searches, is responsible for the institutional support, identified individuals
for the study team and did the oversight of the study direction and scope.
All authors read and approved the final manuscript.
Authors’ information
Mr. James JM. Loan is an ECAT Clinical Lecturer in Neurosurgery at the
University of Edinburgh and Honorary Specialty Registrar at the Institute of
Neurosciences, Glasgow, UK. Dr. Ncedile Mankahla is a consultant neurosurgeon
in the Groote Schuur Hospital and Red Cross Children’s Hospital, Cape Town,
South Africa. Prof. Graeme Meintjes is a professor in the Department of
Medicine, University of Cape Town, a principal investigator in the Clinical
Infectious Diseases Research Initiative (CIDRI), an honorary clinical lecturer in
Imperial College London, a SARChI chair of Lung Infection and Immunity in
Poverty-Related Diseases in the Department of Medicine and a principal
investigator/director of the South African Medical Research Council Clinical
and Community HIV-TB Research Collaborating Centre (C2HTB). Prof. Graham
Fieggen is a Helen and Morris Mauerberger professor and a head of the
division in the University of Cape Town, head of the Clinical Department,
Neurosurgery Groote Schuur Hospital, and a consultant paediatric
neurosurgeon in the Red Cross War Memorial Children’s Hospital.
Ethics approval and consent to participate
Not applicable.
Consent for publication
All authors consent for publication. No other participants were involved.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1College of Medicine and Veterinary Medicine, University of Edinburgh,
Edinburgh, UK. 2Institute of Neurosciences, 1345 Govan Road, Glasgow G51
4TF, UK. 3Groote Schuur Hospital, Observatory, Cape Town, South Africa.
4University of Cape Town, Rondebosch, Cape Town, South Africa. 5Red Cross
War Memorial Children’s Hospital, Rondebosch, Cape Town, South Africa.
Received: 9 March 2017 Accepted: 4 October 2017
References
1. Buonaguro L, Tornesello ML, Buonaguro FM. Human immunodeficiency
virus type 1 subtype distribution in the worldwide epidemic: pathogenetic
and therapeutic implications. J Virol. 2007;81(19):10209–19.
2. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, et al. Reduced rate of
disease development after HIV-2 infection as compared to HIV-1. Science.
1994;265(5178):1587–90.
3. Sabin CA, Lundgren JD. The natural history of HIV infection. Curr Opin HIV
AIDS. 2013;8(4):311–7.
4. Kumar P. Long term non-progressor (LTNP) HIV infection. Indian J Med Res.
2013;138(3):291–3.
Loan et al. Systematic Reviews  (2017) 6:201 Page 9 of 105. Sacktor N. The epidemiology of human immunodeficiency virus-associated
neurological disease in the era of highly active antiretroviral therapy. J
Neuro-Oncol. 2002;8(Suppl 2):115–21.
6. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection.
Lancet Neurol. 2005;4(9):543–55.
7. Croucher A, Winston A. Neurological complications of HIV. HIV and AIDS.
2013;41(8):450–5.
8. Price RW. Neurological complications of HIV infection. Lancet.
1996;348(9025):445–52.
9. Greenberg MS. Hydrocephalus—general aspects. In: Greenberg MS, editor.
Handbook of neurosurgery. 8th ed. New York: Thieme; 2016. p. 394–413.
10. Graybill JR, Sobel J, Saag M, van Der Horst C, Powderly W, Cloud G, et al.
Diagnosis and management of increased intracranial pressure in patients
with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group
and AIDS Cooperative Treatment Groups. Clin Infect Dis. 2000;30(1):47–54.
11. Filippi CG, Ulug AM, Ryan E, Ferrando SJ, van Gorp W. Diffusion tensor
imaging of patients with HIV and normal-appearing white matter on MR
images of the brain. AJNR Am J Neuroradiol. 2001;22(2):277–83.
12. Vinnard C, Macgregor RR. Tuberculous meningitis in HIV-infected
individuals. Curr HIV/AIDS Rep. 2009;6(3):139–45.
13. Figaji AA, Fieggen AG, Peter JC. Endoscopic third ventriculostomy in
tuberculous meningitis. Childs Nerv Syst. 2003;19(4):217–25.
14. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, et al.
Dexamethasone for the treatment of tuberculous meningitis in adolescents
and adults. N Engl J Med. 2004;351(17):1741–51.
15. Clemente Morgado T, Kinsky M, Carrara H, Rothemeyer S, Semple P.
Prognostic value of computed tomography-evident cerebral infarcts in
adult patients with tuberculous meningitis and hydrocephalus treated with
an external ventricular drain. World Neurosurg. 2013;80(6):e255–60.
16. Silver RF, Li Q, Ellner JJ. Expression of virulence of Mycobacterium
tuberculosis within human monocytes: virulence correlates with intracellular
growth and induction of tumor necrosis factor alpha but not with evasion
of lymphocyte-dependent monocyte effector functions. Infect Immun.
1998;66(3):1190–9.
17. Sanduzzi A, Fraziano M, Mariani F. Monocytes/macrophages in HIV infection
and tuberculosis. J Biol Regul Homeost Agents. 2001;15(3):294–8.
18. Jordan CA, Watkins BA, Kufta C, Dubois-Dalcq M. Infection of brain
microglial cells by human immunodeficiency virus type 1 is CD4
dependent. J Virol. 1991;65(2):736–42.
19. Peterson PK, Gekker G, Hu S, Sheng WS, Anderson WR, Ulevitch RJ, et al.
CD14 receptor-mediated uptake of nonopsonized mycobacterium
tuberculosis by human microglia. Infect Immun. 1995;63(4):1598–602.
20. Wallis RS, Vjecha M, Amir-Tahmasseb M, Okwera A, Byekwaso F, Nyole S, et al.
Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced
cytokine expression and elevated beta 2-microglobulin in HIV-1-associated
tuberculosis. J Infect Dis. 1993;167(1):43–8.
21. Curto M, Reali C, Palmieri G, Scintu F, Schivo ML, Sogos V, et al.
Inhibition of cytokines expression in human microglia infected by
virulent and non-virulent mycobacteria. Neurochem Int.
2004;44(6):381–92.
22. Newman PK, Cumming WJ, Foster JB. Hydrocephalus and tuberculous
meningitis in adults. J Neurol Neurosurg Psychiatry. 1980;43(2):188–90.
23. Pappas PG. Managing cryptococcal meningitis is about handling the
pressure. Clin Infect Dis. 2005;40(3):480–2.
24. Offiah CE, Turnbull IW. The imaging appearances of intracranial CNS
infections in adult HIV and AIDS patients. Clin Radiol. 2006;61(5):393–401.
25. Mankahla NR, Rothemeyer SJ. Neurosurgical complications of HIV.
Continuing Med Educ. 2013;31(3):112–3.
26. Tan K, Roda R, Ostrow L, McArthur J, Nath A. PML-IRIS in patients with HIV
infection: clinical manifestations and treatment with steroids. Neurology.
2009;72(17):1458–64.
27. Marais S, Scholtz P, Pepper DJ, Meintjes G, Wilkinson RJ, Candy S.
Neuroradiological features of the tuberculosis-associated immune
reconstitution inflammatory syndrome. Int J Tuberc Lung Dis.
2010;14(2):188–96.
28. Global AIDS update. Geneva, Switzerland: Joint United Nations Programme
on HIV/AIDS; 2016.
29. Van TT, Farrar J. Tuberculous meningitis. J Epidemiol Community Health.
2014;68(3):195–6.
30. Figueroa-Munoz JI, Ramon-Pardo P. Tuberculosis control in vulnerable
groups. Bull World Health Organ. 2008;86(9):733–5.31. Lucas SB, Hounnou A, Peacock C, Beaumel A, Djomand G, N'Gbichi JM, et al.
The mortality and pathology of HIV infection in a west African city. AIDS.
1993;7(12):1569–79.
32. BL MR, Drouin O, Bartlett G, Nguyen Q, Low A, Gavriilidis G, et al. Incidence and
prevalence of opportunistic and other infections and the impact of antiretroviral
therapy among HIV-infected children in low- and middle-income countries: a
systematic review and meta-analysis. Clin Infect Dis. 2016;62(12):1586–94.
33. UNAIDS. South Africa HIV and AIDS Estimates 2015. 2015. [updated 2015;
cited 2016 8 October 2016]. Available from: http://www.unaids.org/en/
regionscountries/countries/southafrica/.
34. Marais S, Pepper DJ, Marais BJ, Torok ME. HIV-associated tuberculous
meningitis—diagnostic and therapeutic challenges. Tuberculosis (Edinb).
2010;90(6):367–74.
35. Denning DW, Armstrong RW, Lewis BH, Stevens DA. Elevated cerebrospinal
fluid pressures in patients with cryptococcal meningitis and acquired
immunodeficiency syndrome. Am J Med. 1991;91(3):267–72.
36. Tully HM, Dobyns WB. Infantile hydrocephalus: a review of epidemiology,
classification and causes. Eur J Med Genet. 2014;57(8):359–68.
37. Bir SC, Patra DP, Maiti TK, Sun H, Guthikonda B, Notarianni C, et al.
Epidemiology of adult-onset hydrocephalus: institutional experience with
2001 patients. Neurosurg Focus. 2016;41(3):E5.
38. Jenkinson MD, Gamble C, Hartley JC, Hickey H, Hughes D, Blundell M, et al.
The British antibiotic and silver-impregnated catheters for
ventriculoperitoneal shunts multi-centre randomised controlled trial (the
BASICS trial): study protocol. Trials. 2014;15:4.
39. Greenberg MS. Treatment of hydrocephalus. In: Greenberg MS, editor.
Handbook of neurosurgery. 8th ed. New York: Thieme; 2016. p. 414–37.
40. Patwardhan RV, Nanda A. Implanted ventricular shunts in the United States:
the billion-dollar-a-year cost of hydrocephalus treatment. Neurosurgery.
2005;56(1):139–44. discussion 44-5
41. Wu Y, Green NL, Wrensch MR, Zhao S, Gupta N. Ventriculoperitoneal
shunt complications in California: 1990 to 2000. Neurosurgery.
2007;61(3):557–62. discussion 62-3
42. Gathura E, Poenaru D, Bransford R, Albright AL. Outcomes of
ventriculoperitoneal shunt insertion in sub-Saharan Africa. J Neurosurg
Pediatr. 2010;6(4):329–35.
43. Bank TW. World Bank Country and Lending Groups 2017 [updated
2017 Fiscal year.
44. UNAIDS. Kenya HIV and AIDS estimates 2015. 2015. [updated 2015; cited 22
October 2016]. Available from: http://www.unaids.org/en/regionscountries/
countries/kenya/.
45. Sharma RM, Pruthi N, Arimappamagan A, Somanna S, Devi BI, Pandey P.
Tubercular meningitis with hydrocephalus with HIV co-infection: role of
cerebrospinal fluid diversion procedures. J Neurosurg. 2015;122(5):1087–95.
46. Nadvi SS, Nathoo N, Annamalai K, van Dellen JR, Bhigjee AI. Role of
cerebrospinal fluid shunting for human immunodeficiency virus-positive
patients with tuberculous meningitis and hydrocephalus. Neurosurgery.
2000;47(3):644–9. discussion 9-50
47. Bach MC, Tally PW, Godofsky EW. Use of cerebrospinal fluid shunts in
patients having acquired immunodeficiency syndrome with cryptococcal
meningitis and uncontrollable intracranial hypertension. Neurosurgery.
1997;41(6):1280–2. discussion 2-3
48. Woodworth GF, McGirt MJ, Williams MA, Rigamonti D. The use of
ventriculoperitoneal shunts for uncontrollable intracranial hypertension
without ventriculomegally secondary to HIV-associated cryptococcal
meningitis. Surg Neurol. 2005;63(6):529–31. discussion 31-2
49. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim
results. UK-TIA Study Group. Br Med J (Clin Res Ed). 1988;296(6618):316-20.
50. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A
practical scale. Lancet. 1974;2(7872):81–4.
51. Jennett B, Bond M. Assessment of outcome after severe brain damage.
Lancet. 1975;1(7905):480–4.
52. RevMan. Review Manager. In: Collaboration TC, editor. 5.0 ed. Copenhagen:
The Cochrane Collaboration; 2008.
53. Reuters T. EndNote X7. 2016.
54. Cochrane handbook for systematic reviews of interventions. Chichester:
Wiley-Blackwell; 2008.
55. National Collaborating Centre for Methods and Tools. Quality Assessment
Tool for Quantitative Studies. ON: McMaster University: ON: McMaster
University; 2008 [updated 13 April 2010]. Available from: http://www.nccmt.
ca/resources/search/14.
Loan et al. Systematic Reviews  (2017) 6:201 Page 10 of 1056. Deeks JJ, Dinnes J, D'amico R, Sowden AJ, Sakarovitch C, Song F, Petticrew
M, Altman DG. Evaluating non-randomised intervention studies. Health
technology assessment (Winchester, England). 2003;7(27):iii–x.
57. GRADEpro. McMaster University 2016. p. [Computer program on www.
gradepro.org].
58. Portegies P, Solod L, Cinque P, Chaudhuri A, Begovac J, Everall I, et al.
Guidelines for the diagnosis and management of neurological
complications of HIV infection. Eur J Neurol. 2004;11(5):297–304.
59. Modi M, Mochan A, Modi G. Management of HIV-associated focal brain
lesions in developing countries. QJM. 2004;97(7):413–21.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
